Sayad Pierre Sargis 4

What Happened Pierre Sargis, Chief Medical Officer of Fennec Pharmaceuticals (FENC), acquired 168 shares on 2026-05-31 as an award/release of previously restricted stock. The filing reports a price of $0.00 for the transaction (code A — award/acquisition) and a total reported cash value of $0, which reflects that these shares were released from restriction rather than purchased for cash.

Key Details

• Transaction date: 2026-05-31; Filing date: 2026-06-01 (timely)
• Transaction type/code: Award/other acquisition (A)
• Shares involved: 168 shares; reported price per share: $0.00; reported cash value: $0
• Shares owned after transaction: not specified in the provided filing excerpt
• Footnote: F1 — "Represents shares released from restriction from shares awarded 3/28/2025"

Context This was a release of restricted shares from a prior award (3/28/2025), not an open‑market purchase or sale. Such releases are typically part of executive compensation and do not, by themselves, indicate a buy/sell signal; however, once restrictions are lifted the shares may be eligible for sale subject to company policies and insider trading rules.